irinotecan

基本解釋

Irinotecan is the specific inhibitor of topoismerase I.
伊立替康是拓撲異構酶I的特異性抑制劑。
The recommended phase II dose of irinotecan was 180 mg/m2.
結果進入研究的病例平均進行了6個療程的化療。
Objective To evaluate the clinical efficacy and adverse effects of irinotecan(CPT-11) combined with 5-Fu/FA in treatment of advanced colorectal cancer.
目的評價CPT-11聯(lián)合5-Fu/FA方案治療晚期結直腸癌的臨床療效及毒副反應。
Objective The aim of this study is to evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced SCLC.
目的觀察伊立替康聯(lián)合順鉑方案治療復治性晚期小細胞肺癌的療效和安全性。
In the 1990s, two additional agents, irinotecan and oxaliplatin, were found to have activity against advanced colorectal cancer.
20世紀90年代出現(xiàn)的另外兩個藥物伊立替康和奧沙利鉑被發(fā)現(xiàn)對晚期結直腸癌有效。